INO
INO clinical trials: INOVIO PHARMACEUTICALS, INC.
Every trial on ClinicalTrials.gov where INOVIO PHARMACEUTICALS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 54
- Trials linked
- 31
- As lead sponsor
- 23
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
INO on the catalyst calendar · INO registry changes
- Primary completion Dec 31, 2027Sponsor estimatePhase 1/Phase 2NCT03491683INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)Inovio Pharmaceuticals · GlioblastomaActive, not recruitingINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 9, 2025ActualPhase 1/Phase 2NCT03502785INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial CarcinomaInovio Pharmaceuticals · Urothelial CarcinomaCompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2022ActualPhase 1/Phase 2NCT04398433INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)Inovio Pharmaceuticals · Respiratory PapillomatosisCompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 19, 2023ActualPhase 2NCT04588428Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy VolunteersInovio Pharmaceuticals · Middle East Respiratory Syndrome Coronavirus (MERS-CoV)CompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 23, 2022ActualPhase 3NCT03721978REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)Inovio Pharmaceuticals · Cervical DysplasiaCompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 13, 2022ActualPhase 2/Phase 3NCT04642638Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 ExposureInovio Pharmaceuticals · Coronavirus InfectionTerminatedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 23, 2020ActualPhase 2NCT03180684Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related...Inovio Pharmaceuticals · Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)CompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 8, 2020ActualPhase 3NCT03185013REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)Inovio Pharmaceuticals · Cervical DysplasiaCompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 16, 2020ActualPhase 2NCT03499795VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or...Inovio Pharmaceuticals · Anal NeoplasmCompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 14, 2022ActualPhase 1NCT04093076Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in GhanaInovio Pharmaceuticals · Lassa FeverCompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2024Sponsor estimatePhase 1NCT05430958Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy VolunteersInovio Pharmaceuticals · Coronavirus InfectionWithdrawnINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 10, 2022ActualPhase 1NCT04336410Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy VolunteersInovio Pharmaceuticals · Coronavirus InfectionCompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2007ActualPhase 3NCT00198328Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell CarcinomaInovio Pharmaceuticals · Head Neck CancerTerminatedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2007ActualPhase 3NCT00198315Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell CarcinomaInovio Pharmaceuticals · Head and Neck CancerTerminatedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 7, 2017ActualPhase 1/Phase 2NCT02172911A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical CancerInovio Pharmaceuticals · Cervical CancerCompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 23, 2017ActualPhase 1/Phase 2NCT02163057Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell CarcinomaInovio Pharmaceuticals · Head and Neck Squamous Cell CancerCompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 21, 2020ActualPhase 1NCT03805984Safety, Tolerability and Immunogenicity of INO-4500 in Healthy VolunteersInovio Pharmaceuticals · Lassa FeverCompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 22, 2018ActualPhase 1NCT02431312Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B SubjectsInovio Pharmaceuticals · Hepatitis BCompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 24, 2018ActualPhase 1NCT02464670Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy VolunteersInovio Pharmaceuticals · Ebola VaccineCompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 9, 2018ActualPhase 1NCT02960594hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of RelapseInovio Pharmaceuticals · Breast CancerCompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2018ActualPhase 1NCT02241369Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and MalignanciesInovio Pharmaceuticals · Aerodigestive Precancerous Lesions and MalignanciesCompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2014ActualPhase 2NCT01304524A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3Inovio Pharmaceuticals · Cervical Intraepithelial NeoplasiaCompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2011ActualPhase 1NCT01188850Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100Inovio Pharmaceuticals · Human Papillomavirus (HPV)CompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 12, 2017ActualPhase 1NCT02514213Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate CancerInovio Pharmaceuticals · Prostate CancerCompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2008ActualPhase 4NCT00198276Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous CancerInovio Pharmaceuticals · CancerCompletedINOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 29 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner